Literature DB >> 11388123

Longitudinal assessment of neuropsychological functioning, psychiatric status, functional disability and employment status in chronic fatigue syndrome.

L A Tiersky1, J DeLuca, N Hill, S K Dhar, S K Johnson, G Lange, G Rappolt, B H Natelson.   

Abstract

The longitudinal course of subjective and objective neuropsychological functioning, psychological functioning, disability level, and employment status in chronic fatigue syndrome (CFS) was examined. The relations among several key outcomes at follow-up, as well as the baseline characteristics that predict change (e.g., improvement), were also evaluated. The study sample consisted of 35 individuals who met the 1988 and 1994 CFS case definition criteria of the Centers for Disease Control (CDC) at intake. Participants were evaluated a mean of 41.9 (SEM = 1.7) months following their initial visit (range = 24-63 months). Results indicated that objective and subjective attention abilities, mood, level of fatigue, and disability improve over time in individuals with CFS. Moreover, improvements in these areas were found to be interrelated at follow-up. Finally, psychiatric status, age, and between-test duration were significant predictors of outcome. Overall, the prognosis for CFS appears to be poor, as the majority of participants remained functionally impaired over time and were unemployed at follow-up, despite the noted improvements.

Entities:  

Mesh:

Year:  2001        PMID: 11388123     DOI: 10.1207/S15324826AN0801_6

Source DB:  PubMed          Journal:  Appl Neuropsychol        ISSN: 0908-4282


  11 in total

Review 1.  Chronic fatigue syndrome: the need for subtypes.

Authors:  Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King
Journal:  Neuropsychol Rev       Date:  2005-03       Impact factor: 7.444

2.  A natural history study of chronic fatigue syndrome.

Authors:  Leonard A Jason; Nicole Porter; Jessica Hunnell; Abigail Brown; Alfred Rademaker; Judith A Richman
Journal:  Rehabil Psychol       Date:  2011-02

3.  CFS: A Review of Epidemiology and Natural History Studies.

Authors:  Leonard A Jason; Nicole Porter; Molly Brown; Valerie Anderson; Abigail Brown; Jessica Hunnell; Athena Lerch
Journal:  Bull IACFS ME       Date:  2009

4.  Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2013-09-10       Impact factor: 3.584

5.  Change in functioning outcomes as a predictor of the course of depression: a 12-month longitudinal study.

Authors:  Carlos G Forero; Elena Olariu; Pilar Álvarez; José-Ignacio Castro-Rodriguez; Maria Jesús Blasco; Gemma Vilagut; Víctor Pérez; Jordi Alonso
Journal:  Qual Life Res       Date:  2018-04-10       Impact factor: 4.147

6.  Validating a measure of myalgic encephalomyelitis/chronic fatigue syndrome symptomatology.

Authors:  Abigail A Brown; Leonard A Jason
Journal:  Fatigue       Date:  2014-07-23

7.  Cognitive impairments associated with CFS and POTS.

Authors:  Lindzi Shanks; Leonard A Jason; Meredyth Evans; Abigail Brown
Journal:  Front Physiol       Date:  2013-05-16       Impact factor: 4.566

8.  The economic impact of ME/CFS: individual and societal costs.

Authors:  Leonard A Jason; Mary C Benton; Lisa Valentine; Abra Johnson; Susan Torres-Harding
Journal:  Dyn Med       Date:  2008-04-08

Review 9.  A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior.

Authors:  Gerwyn Morris; George Anderson; Piotr Galecki; Michael Berk; Michael Maes
Journal:  BMC Med       Date:  2013-03-08       Impact factor: 8.775

Review 10.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics.

Authors:  Gerwyn Morris; Michael Maes
Journal:  BMC Med       Date:  2013-09-17       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.